Register a trial

Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements. New passwords must include at least one lowercase letter, one uppercase letter, one number and one special character (e.g. !#$%&@).
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05259072




Registration number
NCT05259072
Ethics application status
Date submitted
17/02/2022
Date registered
28/02/2022

Titles & IDs
Public title
carDIo-ttranSSfOrm nucLEar Imaging Study
Scientific title
carDIo-ttranSSfOrm nucLEar Imaging Study
Secondary ID [1] 0 0
00023310
Universal Trial Number (UTN)
Trial acronym
DISSOLvE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Amyloidosis 0 0
Transthyretin Amyloid Cardiomyopathy 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Metabolic disorders
Metabolic and Endocrine 0 0 0 0
Other metabolic disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Diagnosis / Prognosis - 99m-technetium pyrophosphate scintigraphy

Patients with transthyretin amyloid cardiomyopathy enrolled in CARDIO-TTRansform - Patients will undergo serial Tc-99m PYP imaging at baseline, week 61 and end of trial


Diagnosis / Prognosis: 99m-technetium pyrophosphate scintigraphy
Imaging test
Intervention code [1] 0 0
Diagnosis / Prognosis
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Primary outcome
Timepoint [1] 0 0
120-140 weeks
Secondary outcome [1] 0 0
Secondary outcome
Timepoint [1] 0 0
120-140 weeks
Secondary outcome [2] 0 0
Secondary outcome
Timepoint [2] 0 0
61 weeks

Eligibility
Key inclusion criteria
* Patients who were screened and eligible to be enrolled or have been already enrolled in the CARDIO-TTRansform randomized clinical trial (NCT04136171) and have a baseline 99m-technetium pyrophosphate planar and SPECT imaging done within 12 months prior to screening for CARDIO-TTRansform.
* Patients have to meet the inclusion and exclusion criteria of CARDIO-TTRansform trial to be enrolled.
* Patient willing to consent for the study and undergo the study procedures.
Minimum age
60 Years
Maximum age
90 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* None

Study design
Purpose
Duration
Selection
Timing
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
19/01/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/12/2023
Sample size
Target
Accrual to date
Final
4
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Oregon

Funding & Sponsors
Primary sponsor type
Other
Name
Oregon Health and Science University
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Ionis Pharmaceuticals, Inc.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Ahmad Masri, MD MS
Address 0 0
Oregon Health and Science University
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Ahmad Masri, MD MS
Address 0 0
Country 0 0
Phone 0 0
503-494-8582
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT05259072